![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DUSP16 |
Gene summary for DUSP16 |
![]() |
Gene information | Species | Human | Gene symbol | DUSP16 | Gene ID | 80824 |
Gene name | dual specificity phosphatase 16 | |
Gene Alias | MKP-7 | |
Cytomap | 12p13.2 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A024RAR2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80824 | DUSP16 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 3.55e-07 | 9.12e-01 | -0.0822 |
80824 | DUSP16 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 2.24e-05 | 8.12e-01 | -0.0809 |
80824 | DUSP16 | RNA-P8T2-P8T2-3 | Human | Lung | AIS | 5.54e-03 | 8.00e-01 | -0.1284 |
80824 | DUSP16 | 047563_1562-all-cells | Human | Prostate | BPH | 9.96e-10 | 4.44e-01 | 0.0791 |
80824 | DUSP16 | 048752_1579-all-cells | Human | Prostate | BPH | 1.17e-23 | 6.57e-01 | 0.1008 |
80824 | DUSP16 | 052095_1628-all-cells | Human | Prostate | BPH | 8.47e-16 | 5.55e-01 | 0.1032 |
80824 | DUSP16 | 052097_1595-all-cells | Human | Prostate | BPH | 1.11e-12 | 4.26e-01 | 0.0972 |
80824 | DUSP16 | 052099_1652-all-cells | Human | Prostate | BPH | 1.12e-22 | 6.20e-01 | 0.1038 |
80824 | DUSP16 | Dong_P1 | Human | Prostate | Tumor | 4.10e-14 | 1.62e-01 | 0.035 |
80824 | DUSP16 | Dong_P3 | Human | Prostate | Tumor | 7.31e-03 | 4.96e-02 | 0.0278 |
80824 | DUSP16 | Dong_P5 | Human | Prostate | Tumor | 5.78e-08 | -2.52e-02 | 0.053 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00066117 | Endometrium | AEH | protein export from nucleus | 17/2100 | 57/18723 | 1.13e-04 | 1.60e-03 | 17 |
GO:000691310 | Endometrium | AEH | nucleocytoplasmic transport | 54/2100 | 301/18723 | 3.24e-04 | 3.62e-03 | 54 |
GO:005116910 | Endometrium | AEH | nuclear transport | 54/2100 | 301/18723 | 3.24e-04 | 3.62e-03 | 54 |
GO:005116810 | Endometrium | AEH | nuclear export | 32/2100 | 154/18723 | 4.02e-04 | 4.29e-03 | 32 |
GO:004340910 | Endometrium | AEH | negative regulation of MAPK cascade | 33/2100 | 180/18723 | 3.04e-03 | 2.15e-02 | 33 |
GO:000661114 | Endometrium | EEC | protein export from nucleus | 20/2168 | 57/18723 | 2.96e-06 | 8.25e-05 | 20 |
GO:000691314 | Endometrium | EEC | nucleocytoplasmic transport | 59/2168 | 301/18723 | 3.31e-05 | 5.65e-04 | 59 |
GO:005116914 | Endometrium | EEC | nuclear transport | 59/2168 | 301/18723 | 3.31e-05 | 5.65e-04 | 59 |
GO:005116814 | Endometrium | EEC | nuclear export | 35/2168 | 154/18723 | 6.36e-05 | 9.48e-04 | 35 |
GO:004340914 | Endometrium | EEC | negative regulation of MAPK cascade | 34/2168 | 180/18723 | 2.69e-03 | 1.95e-02 | 34 |
GO:00069138 | Lung | IAC | nucleocytoplasmic transport | 63/2061 | 301/18723 | 3.50e-07 | 2.54e-05 | 63 |
GO:00511698 | Lung | IAC | nuclear transport | 63/2061 | 301/18723 | 3.50e-07 | 2.54e-05 | 63 |
GO:00511688 | Lung | IAC | nuclear export | 38/2061 | 154/18723 | 1.24e-06 | 6.45e-05 | 38 |
GO:00434098 | Lung | IAC | negative regulation of MAPK cascade | 40/2061 | 180/18723 | 1.05e-05 | 3.30e-04 | 40 |
GO:00163116 | Lung | IAC | dephosphorylation | 75/2061 | 417/18723 | 1.21e-05 | 3.64e-04 | 75 |
GO:00066115 | Lung | IAC | protein export from nucleus | 14/2061 | 57/18723 | 2.93e-03 | 2.61e-02 | 14 |
GO:004340912 | Lung | AIS | negative regulation of MAPK cascade | 39/1849 | 180/18723 | 1.92e-06 | 1.12e-04 | 39 |
GO:001631112 | Lung | AIS | dephosphorylation | 69/1849 | 417/18723 | 1.27e-05 | 4.78e-04 | 69 |
GO:005116813 | Lung | AIS | nuclear export | 33/1849 | 154/18723 | 1.47e-05 | 5.40e-04 | 33 |
GO:000691313 | Lung | AIS | nucleocytoplasmic transport | 52/1849 | 301/18723 | 4.54e-05 | 1.34e-03 | 52 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa040108 | Lung | IAC | MAPK signaling pathway | 62/1053 | 302/8465 | 3.54e-05 | 6.38e-04 | 4.24e-04 | 62 |
hsa0401011 | Lung | IAC | MAPK signaling pathway | 62/1053 | 302/8465 | 3.54e-05 | 6.38e-04 | 4.24e-04 | 62 |
hsa0401021 | Lung | AIS | MAPK signaling pathway | 57/961 | 302/8465 | 6.41e-05 | 9.43e-04 | 6.03e-04 | 57 |
hsa0401031 | Lung | AIS | MAPK signaling pathway | 57/961 | 302/8465 | 6.41e-05 | 9.43e-04 | 6.03e-04 | 57 |
hsa040106 | Lung | MIAC | MAPK signaling pathway | 32/507 | 302/8465 | 1.12e-03 | 1.36e-02 | 9.81e-03 | 32 |
hsa040107 | Lung | MIAC | MAPK signaling pathway | 32/507 | 302/8465 | 1.12e-03 | 1.36e-02 | 9.81e-03 | 32 |
hsa0401010 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
hsa0401013 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
hsa0401022 | Prostate | Tumor | MAPK signaling pathway | 87/1791 | 302/8465 | 8.46e-04 | 3.94e-03 | 2.45e-03 | 87 |
hsa0401032 | Prostate | Tumor | MAPK signaling pathway | 87/1791 | 302/8465 | 8.46e-04 | 3.94e-03 | 2.45e-03 | 87 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DUSP16 | SNV | Missense_Mutation | rs370518275 | c.623N>A | p.Arg208His | p.R208H | Q9BY84 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
DUSP16 | SNV | Missense_Mutation | rs148059278 | c.482N>A | p.Arg161Gln | p.R161Q | Q9BY84 | protein_coding | deleterious(0) | possibly_damaging(0.722) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DUSP16 | SNV | Missense_Mutation | novel | c.130G>A | p.Glu44Lys | p.E44K | Q9BY84 | protein_coding | tolerated(0.11) | benign(0.381) | TCGA-C8-A12X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DUSP16 | SNV | Missense_Mutation | novel | c.130N>A | p.Glu44Lys | p.E44K | Q9BY84 | protein_coding | tolerated(0.11) | benign(0.381) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
DUSP16 | SNV | Missense_Mutation | c.629N>T | p.Pro210Leu | p.P210L | Q9BY84 | protein_coding | deleterious(0) | possibly_damaging(0.876) | TCGA-D8-A1Y3-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
DUSP16 | SNV | Missense_Mutation | novel | c.34N>T | p.Thr12Ser | p.T12S | Q9BY84 | protein_coding | tolerated(0.3) | benign(0.115) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | SD | |
DUSP16 | insertion | Frame_Shift_Ins | novel | c.905dupC | p.Gly303TrpfsTer19 | p.G303Wfs*19 | Q9BY84 | protein_coding | TCGA-B6-A0IC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
DUSP16 | insertion | Frame_Shift_Ins | novel | c.1510_1511insGGGGATTACAGGCACCAGCCACCATGCCCGG | p.His504ArgfsTer44 | p.H504Rfs*44 | Q9BY84 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
DUSP16 | SNV | Missense_Mutation | rs866115319 | c.1832N>A | p.Arg611Gln | p.R611Q | Q9BY84 | protein_coding | tolerated(0.08) | possibly_damaging(0.838) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
DUSP16 | SNV | Missense_Mutation | c.238N>C | p.Asp80His | p.D80H | Q9BY84 | protein_coding | tolerated(0.17) | benign(0.166) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |